Results 311 to 320 of about 93,504 (350)

Combination therapy with oral mineralocorticoid antagonist and ophthalmic glucocorticoid for non-resolving central serous chorioretinopathy.

, 2019
Der‐Chong Tsai, De‐Kuang Hwang, Shih Jen Chen   +2 more
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.

European Heart Journal, 2022
Despite existing treatments, patients with heart failure and chronic kidney disease (CKD) remain at high risk for adverse outcomes and progression to end-stage disease.
A. Pandey, Deepak L. Bhatt, F. Cosentino, N. Marx, O. Rotstein, B. Pitt, Ambirash Pandey, J. Butler, S. Verma   +8 more
semanticscholar   +1 more source

Roles of Mineralocorticoid Receptors in Cardiovascular and Cardiorenal Diseases.

Annual Review of Physiology, 2022
Mineralocorticoid receptor (MR) activation in the heart and vessels leads to pathological effects, such as excessive extracellular matrix accumulation, oxidative stress, and sustained inflammation.
J. Barrera-Chimal, Benjamin Bonnard, F. Jaisser   +2 more
semanticscholar   +1 more source

Increased SGK1 activity potentiates mineralocorticoid/NaCl-induced kidney injury.

AJP - Renal Physiology, 2021
The serum and glucocorticoid-induced kinase 1 (SGK1) stimulates aldosterone-dependent renal Na+ reabsorption and modulates blood pressure. In addition, genetic ablation or pharmacological inhibition of SGK1 limits the development of kidney inflammation ...
Catalina Sierra-Ramos, S. Velazquez-Garcia, A. G. Keskus, Arianna Vastola-Mascolo, A. E. Rodríguez-Rodríguez, S. Luis-Lima, Guadalberto Hernández, J. Navarro-González, E. Porrini, O. Konu, D. Álvarez de la Rosa   +10 more
semanticscholar   +1 more source